Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center, Review Article

Ashraf Ali AlKinani1, Ibrahim Mohammed Alkhrizi2, Saleh Hamdan Alkathiri3, Hani Lahk A Alzubaidi1, Abdulrahman Ahmed Alghanmi1, Abdurrahman Mohammed Alghanim1, Ibrahim Ahmed Alnashri1, Alrwaail Amal Muhaysin B2, Abdulrahman mohammad Almahdi3, Zainab Ali Alabdulmuhsin4

1Faculty of Medicine, Alqufnudah Medical College, Alqufnudah, KSA. 2Faculty of Medicine, Northern Border University, Arar, KSA. 3Intern, Faculty of medicine, Taibah University, KSA. 4Intern, Faculty of Medicine, King Faisal University, Al Ahsa, KSA.

Abstract

Diabetes mellitus is a worldwide epidemic, affecting around half a billion patients and these numbers are expected to grow within the next few years and decades. Placing a huge burden on the health system worldwide, this is because the chronic hyperglycemic state is associated with multiple long-term complications including micro and macrovascular complications in addition patients may develop acute complications such as Diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state, and hypoglycemia, which all may lead to fatal consequences. Our objective was to look into the literature concerning diabetes management and follow-up in particular type 2 PubMed database was used for articles selection, papers were obtained and reviewed. Management of diabetic patients should be individualized but the main principles of care are to achieve adequate glycemic control, through lifestyle modifications, pharmacological and surgical management, in addition to early identification and modification of cardiovascular risk factors that could contribute to developing atherosclerotic diseases one of the main causes of mortality, in addition to establishing scheduled follow-up appointments to screen for complication through physical examination, history taking and laboratory test.

Keywords: Diabetes mellitus, DM, Management, Follow up, Primary health care

INTRODUCTION

Diabetes mellitus is a group of metabolic diseases that causes affected individuals to have hyperglycemia, this happens due to either a defect in insulin secretion, insulin action, or both [1]. diabetes has become a worldwide epidemic, with astronomical numbers of estimated cases, where type 2 diabetes is responsible for up to 425 million patients, and a death toll of 4 million in 2017 [2], while type 1 diabetes accounts for approximate 9 million affected individuals [3]. And these numbers are only expected to increase by 25% in 2030 and 51% in 2045 [4]. Placing a huge burden on the health system worldwide, especially that Chronic hyperglycemic state can have devastating effects on the human body and are associated with long-term damage and dysfunction, in particular retinopathies, nephropathies, neuropathies, and vascular complications [5], in addition, patients may develop acute complications such as Diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state, and hypoglycemia, which all may lead to fatal consequences [6]. In this review, we will go discuss the management and follow-up for diabetic patients in particularly type 2 diabetes.

MATERIALS AND METHODS

PubMed database was used for articles selection, and the following keys used in the mesh ((diabetes) OR (diabetic)) AND (management)) OR (follow-up)). In regards to the inclusion criteria, the articles were selected based on the inclusion of one of the following topics; diabetes, management, and follow-up. Exclusion criteria were all other articles that did not have one of these topics as their primary endpoint.

Review

Management approach to patients with diabetes has multiple aspects and should be tailored based on individual needs and patients-factors [7], but we will try to summarize and present the general recommendations based on the latest evidence. We can classify the management into 3 broad categories which are glycemic control, prevention of complications, and  

management of short- and long-term complications, we will focus in our discussion on the former two.

**Glycemic Control**

The cornerstone of management in diabetic patients is proper glycemic control, as data from numerous research have found that the incidence of diabetic complications is directly related to poor glycemic control [8]. Latest recommendations advocate for using glycated hemoglobin (A1C) for glycemic assessment as it is considered a reliable measure of chronic hyperglycemia and a good predictor for long-term diabetes complications [9]. The target goal of glycated hemoglobin level should be individualized, balancing the health benefit on one hand and adverse effects such as hypoglycemic attacks and additional expenses on the other hand. But in general, most young patients without any established complications the recommended goal is <7 percent (53 mmol/mol) [10], to achieve such levels patients should aim and maintain daily Fasting glucose between 80 - 130 mg/dL and postprandial glucose below 180 mg/dL [11], but older patients with limited life expectancy, comorbid conditions or who already have developed complication a less strict control up to 8 percent (64 mmol/mol) or higher is desirable [10].

In newly diagnosed type 2 diabetic patients, blood glucose levels can be managed by a variety of lifestyle changes and non-pharmacological measures including a healthy and balanced diet, physical exercise, weight reduction, and bariatric surgery. In addition to patient education and consultation about self-management and care [12]. If glucose control was inadequate, non-compliance of patients or an initially high A1C pharmacological therapy can be deployed as we will discuss in the next section of the paper.

As for type 1 diabetic patients intensive insulin therapy should be commenced as early as possible in all patients as it has been proven to lower the risk of both micro and macrovascular complication [13, 14], some experts may recommend tighter control of A1C level below 6.5% but there are no long term data to support that, especially that the tighter the control the more chances of side effect which may include financial burden, weight gain and more dreadfully recurrent hypoglycemic attacks that could prove to be fatal [15], both traditional method of insulin administration using multiple daily insulin (MDI) injections and new developed continuous subcutaneous delivery of a rapid-acting insulin preparation via a pump (CSII) achieve similar outcomes and choice is mainly based on personal preferences of patients [16].

**Hypoglycemic Medications for Type 2 Diabetes**

With a plethora of developed hypoglycemic drugs that are available, making the optimal choice of medication based on each patient’s unique characteristic and needs is a difficult task, we will briefly discuss the main pharmacological options to help guide physicians for making the right choice.

**Metformin**

The recommended initial choice of monotherapy in newly diagnosed type 2 asymptomatic patients, is due to its comparable glycemic control to other medications, weight reducing properties, and reduction of cardiovascular risks [17-19], in addition to being more affordable and with a relatively safer side effect profile, such as fewer hypoglycemic attacks [20], the full extent of its mechanism of action is still not fully understood but the main effect is inhibiting the gluconeogenesis in the liver, other effects include insulin sensitization and gut alteration but are yet to be fully studied. The most common side effect is GI upset and vitamin B12 deficiency while the most serious is lactate acidosis especially in predisposed patients who suffer from a hepatic impairment, heart failure, and chronic kidney disease (CKD), therefore metformin is contraindicated to be prescribed in patients with eGFR less than 30 mL/min or severe hepatic or cardiac impairment, dosing starts with 500 mg once per day taken in the evening, which could be increased with gradual titration till reaching the maximum dose of 2grams/day [21]. In case of intolerance or inadequate control within 3 months despite reaching maximum dose a second line of therapy could be added.

**Sulfonylurea**

sulfonylureas are a group of drugs that exert their action on pancreatic β-cells causing a rise in insulin plasma concentrations, in addition to a reduction in insulin hepatic clearance, these drugs are cheap, generally safe, and could be used as monotherapy as a combination, put patient should be educated on possible side effect especially the hypoglycemic attacks and weight gain, therefore they are usually avoided in the elderly who are at high risk of complications if hypoglycemia does occur, additionally they are associated with increased cardiovascular complication and worst prognosis in patients who develop the cardiac event [22].

**GLP-1 RA (receptor agonist)**

Are a group of analogues similar to the naturally produced GLP-1 hormone, which acts on β Cells leading to increase in insulin production in responses to high glucose levels, additionally it causes a reduction in glucagon release, slowing of gastric emptying, decrease in appetite and mild weight reduction, a key difference between these analogues and the natural hormone is that former is more resistant to degradation by DPP-4 enzymes and thus they exert a more potent action, GLP-1 RA medications are expensive and usually indicated as an add-on therapy in individuals with a co-morbid atherosclerotic disease where there have been found to decrease mortality from CVS complications or with history of recurrent hypoglycemia, but they are not recommended to be used in patients with eGFR <30 mL/min or with history of pancreatitis as they may cause flare-ups, their most prevalent side effects are gastrointestinal complains, a good point to keep in mind that studies have demonstrated no additional benefit was observed when...
combined GPP-4 inhibitors and thus such regimen should be avoided [23, 24].

**DPP-4 inhibitor**
The mechanism of action in these drugs is similar to GLP RA mentioned above, with the difference being in site action where they act on the DPP-4 enzyme inhibiting its break down of GLP-1 hormone, and that they produce a milder degree of effect if compared to GLP-1 RA, in addition to being inferior regarding mortality reduction, frequent side effects include respiratory tract infection, skin and musculoskeletal symptoms but don’t seem to increase the incidence of pancreatitis, As a result of what’s mentioned earlier their use is mainly in patients who develop intolerance or adverse effects to GLP-1 RA [25-27].

**Thiazolidinedione**
Thiazolidinedione directly decreases insulin resistance, which subsequently causes a decrease in insulin requirement, alteration in adipose tissue distribution, decrease in plasma LDL and free fatty acid concentration, increases in HDL, and decrease in cardiovascular risk factors, henceforth are a good candidate inpatient at risk of cardiovascular events, similar to sulfonylureas they can lead to weight gain, but more commonly edema and fluid overload which could have a catastrophic effect on a patient with heart failure and therefore is generally contraindicated in such patients, other rare side effects include bladder cancer and hepatitis [28].

**SGLT2 inhibitor**
They act on proximal tubules of the kidney inhibiting glucose transporters and enhancing excretion, due to such mechanism hypoglycemia is a rare complication, also they promote modest weight loss and decline blood pressure, they are a favorable option in patients with heart failure, atherosclerotic disease, and chronic kidney disease with some experts calling it the drug of choice for cardiorenal protection, adverse effects include genitourinary infections, increased risk of fractures, foot amputations, DKA and AKI and henceforth should be avoided in patient with history developing such complications [29, 30].

**Insulin Therapy in Type 2 Diabetes**
Insulin therapy is recommended to be initiated if AIC level at presentation was >9% or glycemic control was inadequate despite using optimal treatment [31], it could be used as monotherapy or in conjunction to the previously used oral hypoglycemic medications, but if patient is on Sulfonylureas or Thiazolidine then a change of regimen is warranted to any of the following drugs Metformin, GLP-1 RA, DPP-4 inhibitors, and SGLT2, this occurs mainly due to increased risk of adverse effects chiefly hypoglycemia [32], a good dose to start therapy with is 0.1-0.2 units/per kg/per day of basal or long acting insulin injected early in morning or prior to bedtime insulin dose which is known as augmentation dose, this dose could be tittered gradually by 2 to 4 units/per week till reaching the desired glycemic control, guided by frequent measures of fasting blood glucose levels [33], if patients don’t achieve optimal control despite reaching 0.5 unit/kg then switching to a replacement dose administered through multiple daily injections (MDI) or an insulin pump are both viable options [31], but detailed insulin regimen and options are beyond the scope of this article and won’t be discussed here, a crucial points for achieving good outcomes of therapy is patient education, as they should receive a thorough and extensive education on how to monitor their glucose levels, adjusting the dose based on consumed food or physical exercise, healthy and harmful eating habits and what possible side effects they may experience such as weight gain and hypoglycemia, in addition if family members are available they could be involved and taught for example on how to help incases of hypoglycemic attack [34].

**Surgical Management**
Numerous researches have demonstrated positive outcomes in an obese patient with type 2 diabetes undergoing bariatric surgical procedures, these effects range from improved glycemic control to the cessation of insulin therapy and full remission for a while, some studies have even shown that surgeries had better glycemic control compared to medical therapy [35]. But not all patients will have such astonishing results and the key point for good outcomes is choosing appropriate candidates for surgery such as a patient with BMI >35 kg/m2 [36].

**Cardiovascular Risk Reduction**
Diabetic patients are more prone to developing atherosclerotic cardiovascular complications which are considered one of the main causes of mortality in this population, therefore a major aspect of treatment is identifying and managing other risk factors of developing CVD, these include smoking cessation and weight reduction, another risk factor to alter is hypertension to maintain blood pressure <140/90, but if a patient has an established ASCVS or 10-year ASCV risk ≥15% then a more stringent goal of <130/80 is more desirable, if patients have hypertension and associated proteinuria then the prescription of either ACEI or ARBs is recommended, in addition to correction of any dyslipidemia using statins or other lipid-lowering medications, finally patients who have established ASCVS should start using aspirin therapy at a dose of 75–162 mg/day, on the other hand, the use of aspirin as a mean of primary prevention is still debatable and further research need to be conducted [37, 38].

**Follow up**
As we have discussed through this paper diabetic patients are at risk of developing a wide array of possible complications, therefore the implementation of routine follow-ups and evaluations is necessary for continuous assessment of glycemic control, and early identification and management of any arising complication.
Clinic Visits
A diabetic patient should have at least 2 – 4 appointments per year with their primary care physician, during which the doctor should perform a thorough physical examination with blood pressure measurement and foot examination, additionally, a full history must be taken from patients looking for any symptoms suggesting complications, also physician should counsel their patient regarding weight loss, and smoking cessation, lastly patients need to undergo a dilated eye examination annually performed by an ophthalmologist, but if retinopathy was detected then the frequency of examination should be increased to guide therapy [38].

Laboratory Test
Glycemic control of patient needs to be assessed using A1C level at 6 months intervals assuming good control, but suboptimal glucose level will warrant testing at 3 months increments till adequate control is achieved, moreover lipid profile should be taken as part of initial evaluation and repeated every 5 years if the result were within the desired range, however, if a patient were found to have dyslipidemia then a follow-up test after 1-3 months post-initiation of management is needed and future tests to be done once per year, finally patients are recommended to assess their urinary albumin once yearly if unfortunately urinary albumin was found to be >30 mg/g increasing frequency of testing is needed [38].

Conclusion
Management of diabetic patients should be individualized taking into consideration each patient’s unique characteristics and needs, but the main principles of care are to achieve and maintain adequate glycemic control through the use of lifestyle modifications, pharmacological and surgical management, in addition to early identification and modification of cardiovascular risk factor such as smoking, hypertension, dyslipidemia and obesity which all could contribute to developing atherosclerotic diseases one of the main causes of mortality, also providing proper patient education and support to aid him in his therapeutic journey, finally to encourage patient to have routinely scheduled follow-up appointments to screen for complication through physical examination, history taking and laboratory test.

Acknowledgments: None
Conflict of Interest: None
Financial Support: None
Ethics Statement: None

References

AlKinani et al.: Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center, Review Article


